Study Name: Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regim
27 locations found
- Novartis Investigative Site
Location: Glendale, Arizona 85308
- Novartis Investigative Site
Location: Concord, California 94520
- Novartis Investigative Site
Location: Fresno, California 93710
- Novartis Investigative Site
Location: Sacramento, California 95816
- Novartis Investigative Site
Location: San Francisco, California 94118
- Novartis Investigative Site
Location: San Marino, California 91108
- Novartis Investigative Site
Location: Farmington, Connecticut 06030
- Novartis Investigative Site
Location: Jacksonville, Florida 32204
- Novartis Investigative Site
Location: Jacksonville, Florida 32216
- Novartis Investigative Site
Location: South Miami, Florida 33143
- Novartis Investigative Site
Location: West Palm Beach, Florida 33409
- Novartis Investigative Site
Location: Champaign, Illinois 61820
- Novartis Investigative Site
Location: Indianapolis, Indiana 46256
- Novartis Investigative Site
Location: Overland Park, Kansas 66215
- Novartis Investigative Site
Location: Boston, Massachusetts 02111
- Novartis Investigative Site
Location: Boston, Massachusetts 02114
- Novartis Investigative Site
Location: Fridley, Minnesota 55432
- Novartis Investigative Site
Location: St. Louis, Missouri 63117
- Novartis Investigative Site
Location: Las Vegas, Nevada 89119
- Novartis Investigative Site
Location: Verona, New Jersey 07044
- Novartis Investigative Site
Location: Greensboro, North Carolina 27408
- Novartis Investigative Site
Location: High Point, North Carolina 27262
- Novartis Investigative Site
Location: Cleveland, Ohio 44106
- Novartis Investigative Site
Location: Charleston, South Carolina 29425
- Novartis Investigative Site
Location: Greer, South Carolina 29651
- Novartis Investigative Site
Location: Dallas, Texas 75231
- Novartis Investigative Site
Location: Orem, Utah 84097
|